FEATURES


Viewpoints

Human Papillomavirus (HPV) Test May Be More Accurate Than Pap Test for Cervical Cancer Screening

Human Papillomavirus (HPV) Test May Be More Accurate Than Pap Test for Cervical Cancer Screening

A review of data suggests that HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.

Venous Thrombo-embolism Prophylaxis in the Outpatient Oncology Setting

Venous Thrombo-embolism Prophylaxis in the Outpatient Oncology Setting

While guidelines recommend against routine use, further investigation and data collection on this topic is warranted.

Feature Articles

New Therapies in T-cell Lymphoma

New Therapies in T-cell Lymphoma

Biomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in early- and late-phase clinical trials involving patients with T-cell lymphoma.

Diarrhea and Patients With Cancer

Diarrhea and Patients With Cancer

Diarrhea is a treatment symptom as common as hair loss but with deadlier implications.

Cervical Cancer Rates May Be Higher in Older Women Than Previously Reported

Cervical Cancer Rates May Be Higher in Older Women Than Previously Reported

Rate of cervical cancer in African-American women is higher than what was previously recognized.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

ZYKADIA™ (ceritinib)

ZYKADIA™ (ceritinib)

This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Table ...

From the Advisory Board

The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma

The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma

Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs